RBC Capital Maintains Outperform on Nurix Therapeutics, Raises Price Target to $36
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
RBC Capital analyst Brian Abrahams maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $33 to $36.
RBC Capital analyst Brian Abrahams maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $33 to $36.